OpenAI acquires Orchestra Bio to improve drug development workflows

OpenAI has acquired Orchestra Bio, a company building specialized AI software that models how delays in drug discovery projects affect clinical timelines. OpenAI plans to integrate the technology into its life science platform. Terms of the purchase were not disclosed.